Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome

American Journal of Medical Genetics, Part A

Volumn 164, Issue 1, 2014, Pages 141-155

  Wheeler, Anne ^a   Raspa, Melissa ^b   Bann, Carla ^b   Bishop, Ellen ^b   Hessl, David ^c,d   Sacco, Pat ^e   Bailey, Donald B ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anxiety; Attention deficit hyperactivity disorder; Behavior symptoms; Fragile X syndrome

Indexed keywords

ABERRANT BEHAVIOR CHECKLIST; ADULT; AGE; ANXIETY; ANXIETY DEPRESSION AND MOOD SCALE; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION HYPERACTIVITY ITEMS FROM THE SYMPTOM INVENTORY; CAREGIVER BURDEN; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; ADOLESCENT; AGED; ATTENTION; BEHAVIOR; CAREGIVER; CHECKLIST; HEALTH SURVEY; MIDDLE AGED; PRESCHOOL CHILD; PSYCHOLOGY; PSYCHOMETRY; REGISTER; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANXIETY; ATTENTION; BEHAVIOR; CAREGIVERS; CHECKLIST; CHILD; CHILD, PRESCHOOL; FEMALE; FRAGILE X SYNDROME; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; REGISTRIES; YOUNG ADULT;

EID: 84890596334     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36232     Document Type: Article

References (60)

1. Aman MG. 2010. The aberrant behavior checklist: An annotated bibliography. Columbus, OH: The Ohio State University. Unpublished manuscript.
2. Aman MG, Singh NN. 1986. Aberrant Behavior Checklist Manual. East Aurora, NY: Slosson Educational Publications.
3. Aman MG, Singh NB. 1994. Aberrant Behavior Checklist-Community, supplementary manual. East Aurora, NY: Slosson Educational Publications.
4. Aman MG, Burrow WH, Wolford PL. 1995. The aberrant behavior checklist-Community version: Factor validity and effect of subject variables for adults in group homes. Am J Ment Retard 100:283-292.
5. Aman MG, Smedt GD, Derivan A. 2002. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 14:1337-1346.
6. Arnold LE, Vitiello B, McDougle C. 2003. Parent-defined target symptoms respond to resiperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42:1443-1450.
7. Backes M, Genc B, Schreck J, Doerfler W, Lehmkuhl G, von Gontard A. 2000. Cognitive and behavioral profile of fragile X boys: Correlations to molecular data. Am J Med Genet 95:150-156.
8. Bailey DB, Sideris J, Roberts J, Hatton D. 2008a. Child and genetic variables associated with maternal adaptation to fragile X syndrome: A multidimensional analysis. Am J Med Genet Part A 146A:720-729.
9. Bailey DB, Raspa M, Olmsted M, Holiday D. 2008b. Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am J Med Genet Part A 146A:2060-2069.
10. Bailey DB, Raspa M, Olmsted MG. 2010. Using a parent survey to advance knowledge about the nature and consequences of fragile X syndrome. Am J Intellect Dev Dis 115:447-460.
11. Bailey DB, Raspa M, Bishop E, Olmsted M, Mallya U, Berry-Kravis E. 2012a. Medication utilization for targeted symptoms in children and adults with fragile X syndrome-U.S. survey. J Dev Behav Pediatr 33:62-69.
12. Bailey DB, Raspa M, Bishop E, Mitra D, Martin S, Wheeler A, Sacco P. 2012b. Caregiver burden in fragile X syndrome. J Dev Behav Pediatr 33:705-712.
13. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. 1995. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 95:744-752.
14. Berry-Kravis E, Potanos K. 2004. Psychopharmacology in fragile X syndrome-Present and future. Ment Retard Dev Disabil Res Rev 10:42-48.
15. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpener RL, Bear MF, Hagerman RT. 2012. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med 19:152ra127.
16. Boyle L, Kaufmann WE. 2010. The behavioral phenotype of FMR1 mutations. Am J Med Genet Part C 154C:469-476.
17. Brinkley J, Nations L, Abramson RK, Hall A, Wright HH, Gabriels R, Gilbert JR, Pericak-Vance MAO, Cuccaro ML. 2007. Factor analysis of the Aberrant Behavior Checklist in individuals with autism spectrum disorders. J Autism Dev Disord 37:1949-1959.
18. Brown EC, Aman MG, Havercamp SM. 2002. Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Res Dev Disabil 23:45-60.
19. Ching H, Pringsheim P. 2012. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 16:CD009043.
20. Cordeiro L, Ballinger E, Hagerman R, Hessel D. 2011. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. J Neurodev Disord 3:57-67.
21. Dekker MC, Nunn RJ, Einfeld SE, Tonge BJ, Koot HM. 2002. Assessing emotional and behavioral problems in children with intellectual disability: Revisiting the factor structure of the developmental behavior checklist. J Autism Dev Disord 32:601-610.
22. Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. 2011. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl) 216:85-90.
23. Esbensen A, Benson B. 2006. A prospective analysis of life events, problem behaviours and depression in adults with intellectual disability. J Intellect Disabil Res 50:248-258.
24. Esbensen AJ, Rojahn J, Aman MG, Ruedrich S. 2003. Reliability and validity of an assessment instrument for anxiety, depression and mood among individuals with mental retardation. J Autism Dev Disord 33:617-629.
25. Gabis LV, Baruch YK, Jokel A, Raz R. 2011. Psychiatric and autistic comorbidity in fragile X syndrome across ages. J Child Neurol 26:940-948.
26. Gadow KD, DeVincent CJ. 2012. Schizophrenia spectrum traits in prepubertal children with autism spectrum disorder. J Autism Dev Disord, published online February 24, 2012, doi: 10.1007/s10803-012-1473-4
27. Gadow KD, Sprafkin J. 2010. Child and adolescent symptom inventory-4R. Stony Brook, NY: Checkmate Plus.
28. Gadow KD, Sprafkin J, Weiss M. 2004. Adult inventory-4. Stony Brook, NY: Checkmate Plus.
29. Gadow KD, Guttmann-Steinmetz S, Rieffe C, DeVincent CJ. 2012. Depression symptoms in boys with autism spectrum disorder and comparison samples. J Autism Dev Disord 42:1353-1363.
30. Gerber F, Bessero S, Robbiani B, Courvoisier DS, Baud MA, Traore MC, Blanco P, Giroud M, Carminati GG. 2011. Comparing residential programmes for adults with autism spectrum disorders and intellectual disability: Outcomes of challenging behavior and quality of life. J Intellect Disabil Res 55:918-932.
31. Gothelf D, Furfaro JA, Hoeft F, Eckert MA, Hall SS, O'Hara R, Erba HW, Ringel J, Hayashi KM, Patnaik S, Golianu B, Kraemer HC, Thompson PM, Piven J, Reiss AL. 2007. Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Ann Neurol 63:40-51.
32. Gross C, Berry-Kravis EM, Bassell GJ. 2012. Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacol Rev 37:178-195.
33. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M. 2009. Advances in the treatment of fragile X syndrome. Pediatrics 123:378-390.
34. Hall SS, Burns DD, Reiss AL. 2007. Modeling family dynamics in children with fragile X syndrome. J Abnorm Child Psychol 35:29-42.
35. Hall SS, Lightbody AA, Huffman LC, Lazzeroni LC, Reiss AL. 2009. Physiological correlates of social avoidance behavior in children and adolescents with fragile x syndrome. J Am Acad Child Adolesc Psychiatry 48:320-329.
36. Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. 2012. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology 37:509-518.
37. Hatton DD, Hooper SR, Bailey DB, Skinner M, Sullivan K, Wheeler A. 2002. Problem behavior in boys with fragile X syndrome. Am J Med Genet 108:105-116.
38. Heilman KJ, Harde ER, Zageris DM, Berry-Kravis E, Porges SW. 2011. Autonomic regulation in fragile X syndrome. Dev Psychobiol 53:785-795.
39. Hessl D, Glaser B, Dyer-Friedman Blasey C, Gunnar M, Hastie T, Reiss A. 2002. Cortisol and behavior in fragile X syndrome. Psychoneuroendocrino 27:855-872.
40. Hessl D, Tassone F, Cordeiro L, Koldewyn K, McCormick C, Green C, Wegelin J, Yuhas J, Hagerman R. 2008. Aggression and stereotypic behavior in males with fragile X syndrome: Moderating secondary genes in a "single gene" disorder. J Autism Dev Dis 38:184-189.
41. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe D, Johns G, Gomez-Mancilla B. 2011. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64ra1.
42. Ji NY, Capone GT, Kaufmann WE. 2011. Autism spectrum disorder in Down syndrome: Cluster analysis of aberrant behavior checklist data supports diagnosis. J Intellect Disabil Res 55:1064-1077.
43. Lecavalier L, Gadow KD, Devincent CJ, Houts CR, Edwards MC. 2011. Validity of DSM-IV syndromes in preschoolers with autism spectrum disorders. Autism 15:227-243.
44. Matson JL, Mahan S, Hess JA, Fodstad JC, Neal D. 2010. Progression of challenging behaviors in children and adolescents with Autism Spectrum Disorders as measured by the Autism Spectrum Disorders-Problem Behaviors for Children (ASD-PBC). Res Autism Spec Dis 4:400-404.
45. McCarthy A, Cuskelly M, van Kraayenoord CE, Cohen J. 2006. Predictors of stress in mothers and fathers of children with fragile X syndrome. Res Dev Disabil 27:688-704.
46. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, for Research Units on Pediatric Psychopharmacology Autism Network. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321.
47. Murphy O, Healy O, Leader G. 2009. Risk factors for challenging behaviours for 157 children with autism spectrum disorder in Ireland. Res Autism Spect Dis 3:474-482.
48. Paclawskyj TR, Matson JL, Banburg JW, Baglio CS. 1997. A comparison of the diagnostic assessment for the severely handicapped-II (DASH-II) and the aberrant behavior checklist (ABC). Res Dev Disabil 18:289-298.
49. Paribello C, Tao L, Folilno A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. 2010. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 11:91.
50. Roberts JE, Boccia ML, Bailey DB, Hatton D, Skinner M. 2001. Cardiovascular indices of physiological arousal in boys with fragile X syndrome. Dev Psychobiol 39:107-123.
51. Rojahn J, Rowe EW, Kasdan S, Moore L, van Ingen DJ. 2011. Psychometric properties of the Aberrant Behavior Checklist, the Anxiety Depression and Mood Scale, the Assessment of Dual Diagnosis, and the Social Performance Survey Schedule in adults with intellectual disabilities. Res Dev Disabil 32:2309-2320.
52. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, Hessl D. 2012. Psychometric study of the Aberrant Behavior Checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 42:1377-1392.
53. Scerif G, Longhi E, Cole V, Karmiloff-Smith A, Cornish K. 2012. Attention across modalities as a longitudinal predictor of early outcomes: The case of fragile X syndrome. J Child Psychol Psychiatry 53:641-650.
54. Shea S, Turgay A, Carroll A, Shulz M. 2004. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 14:634-641.
55. Sullivan K, Hatton D, Hammer J, Sideris J, Hooper S, Ornstein P, Bailey D. 2006. ADHD symptoms in children with FXS. Am J Med Genet Part A 140A:2275-2288.
56. Symons FJ, Byiers BJ, Raspa M, Bishop E, Bailey DB. 2010. Self-injurious behavior and fragile X syndrome: findings from the National Fragile X Survey. Am J Intellect Dev Disabil 115:473-481.
57. Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, Hutchison JA, Di Raimo FR, Tabolacci E, Neri G. 2010. Treatment with valproic acid emeliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet Part A 152A:1420-1427.
58. Tranfaglia MR. 2011. The psychiatric presentation of fragile X: Evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci 33:337-348.
59. Van Bellinghen M, de Troch C. 2001. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychophamacol 11:5-13.
60. Wheeler AC, Skinner DG, Bailey DB. 2008. Perceived quality of life in mothers of children with fragile X syndrome. Am J Ment Retard 113:159-177.